Swipe Left For English News
中国，上海
2023年2月10日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布公司荣获《财资》2022年度ESG企业大奖-铂金奖，这也是公司连续两年获此殊荣。
作为国际权威财经新闻及商业研究机构，《财资》重点关注企业的环境、社会和公司治理（ESG）以及可持续性表现。“《财资》ESG企业大奖”每年对候选企业的多个指标进行评估，包括能源消耗和温室气体排放、废弃物和水资源管理、供应商行为准则、可持续性融资和公司治理等。
陈智胜
博士
药明生物首席执行官
环境、社会和公司治理（ESG）委员会主席
我们很高兴再次获得《财资》颁发的ESG铂金奖，这也是对于我们作为行业内ESG领导者地位的认可。在过去的一年里，药明生物在ESG方面的坚定承诺和积极行动得到了广泛认可，并获得多家国际评级机构给出的优秀评级。非常感谢全球合作伙伴、投资者和社会公众对我们的信赖。我们将继续践行ESG战略并将之打造成为公司的核心竞争力，更好地赋能全球合作伙伴，造福广大患者。
药明生物将ESG视为业务发展战略的重要组成部分，并全面提升各个维度的可持续发展表现。2022年，药明生物成立ESG专项工作组，针对核心ESG议题实现高效跨部门协作，在气候变化、基地可持续发展、“多元化、平等与包容（DEI）”、负责任治理和可持续采购等方面制定详实路线图及行动方案，并稳步实现各阶段目标。此外，药明生物投入专项资源，积极践行企业社会责任，做负责任的企业公民。2022年，公司捐赠善款支援四川地震救灾，并以行动持续助力罕见病弱势群体。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过10000名员工。凭借这些员工组成的专业服务团队，以及卓越的技术和洞见，公司为客户提供高效经济的生物药解决方案。
药明生物将环境、社会和治理（ESG）视为业务发展和企业精神的重要组成部分，并致力于成为全球生物药CRDMO领域的ESG领导者，例如应用更绿色环保的新一代生物制药技术和能源等引领行业发展。公司成立了由首席执行官领导的ESG委员会，全面落实ESG战略并践行可持续性发展承诺。
更多信息，请访问：www.wuxibiologics.com
WuXi Biologics Receives The Asset ESG Corporate Platinum Award for Second Consecutive Year
Shanghai,
Feb. 10, 2023
WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it received the “Platinum Award” in The Asset ESG Corporate Awards 2022. This marks the second consecutive year the company has received the award.
As a widely recognized business news and research organization, The Asset evaluates companies regarding their Environmental, Social, and Governance (ESG) responsibility and sustainability. For its annual ESG Corporate Awards, the organization reviews a wide range of metrics, including waste and water management, energy consumption and GHG emissions, supplier codes of conduct, sustainability financing, and corporate governance.
Dr. Chris Chen
CEO of WuXi Biologics
Chairman of the company's Environmental, Social, and Governance (ESG) Committee
We are very pleased to once again receive The Asset's Platinum Award, which demonstrates our role as an industry ESG leader. During the past year, WuXi Biologics' ESG commitments and proactive efforts were widely recognized, earning excellent marks from multiple rating agencies and index providers. We appreciate the trust that global partners, investors and local communities have in us. We will continue to make ESG a core competency and to implement related strategies – the better to enable our global partners for the benefit of patients worldwide.
WuXi Biologics views ESG responsibilities as an integral component of its business strategy and works to meet firm targets and achieve sustainable performance. In 2022, the company established cross-functional task forces to work on core ESG topics: Climate Change; Site Sustainability; Diversity, Equity, and Inclusion (DEI); Responsible governance; and Sustainable Procurement. It has made continual progress in these areas. Additionally, WuXi Biologics shoulders social responsibilities with dedicated resources and contributions. In 2022, the company continued its tradition of helping patients with rare diseases, and also made donations to support earthquake rescue in Sichuan.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit:
www.wuxibiologics.com
精选阅读
